Sensorion at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Sensorion brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV gene therapy for inherited hearing loss. Both topics address DFNB1A deafness caused by GJB2 faults, including whether the delivered gene restores working gap junctions between cells.
| Organization | ESGCT 2026 Attendance |
|---|---|
Sensorion Montpellier, France | |
Develops treatments for hearing loss, including AAV gene therapies for otoferlin deficiency and GJB2-related deafness. | Poster Wed Oct 28 1:30pm–3:30pm In vitro assessment of functional gap junctions for novel AAV-based GJB2 gene therapy developed to treat DFNB1A deafness Poster Thu Oct 29 2:00pm–4:00pm SENS-601, a Novel Adeno Associated Vector-Based Gene Therapy as a Treatment for the Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A) |
Instantly find 20 buyers from Sensorion
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction